Adlai Nortye Group Ltd. - American Depositary Shares (ANL)
ANL moved a median of 0.00% 30 minutes after news, and +0.68% by the close. How ANL actually reacts to news — the realized, point-in-time move the market made, measured across 83 labeled events over the last three years with zero look-ahead.
ANL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 60 |
| 30-min | 0.00% | 48% | 71 |
| 60-min | -0.00% | 49% | 74 |
| to close | +0.68% | 55% | 80 |
| Middle 50% of ANL reactions | -1.64% to +2.15% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 83 |
Half of all Adlai Nortye Group Ltd. - American Depositary Shares news events land between -1.64% and +2.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ANL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | +1.03% | 78% | -1.65% |
| Rating reiterations | 13 | -1.18% | 8% | -1.09% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ANL ranks against every other measured name →
That’s how ANL usually reacts — get an email when it moves on news →Email me when ANL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANL's baseline. Nothing else.
Recent ANL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab | Press release | GlobeNewswire | +1.38% | +7.66% | |
| Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations | Press release | GlobeNewswire | -0.73% | +0.82% | |
| Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC | Press release | GlobeNewswire | +1.22% | +2.58% | |
| Form 6-K Adlai Nortye Ltd. For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | +0.32% | +0.56% | |
| Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress | Press release | GlobeNewswire | +0.16% | +4.08% | |
| Form 6-K Adlai Nortye Ltd. For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | +4.08% | |
| Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia | Press release | GlobeNewswire | -2.23% | +0.00% | |
| Form 6-K Adlai Nortye Ltd. For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -2.23% | +0.00% | |
| Form 6-K Adlai Nortye Ltd. For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | +0.69% | +5.97% | |
| Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 | Press release | GlobeNewswire | -2.15% | +8.40% | |
| Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists | Press release | GlobeNewswire | +1.07% | -5.71% | |
| Form EFFECT Adlai Nortye Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +5.05% | +16.74% | |
| Form F-3/A Adlai Nortye Ltd. | SEC filing · Form F-3 | SEC EDGAR | +0.03% | -1.20% | |
| Form F-3/A Adlai Nortye Ltd. | SEC filing · Form F-3 | SEC EDGAR | +0.83% | -7.79% | |
| Adlai Nortye Announces $150.0 Million Private Placement Equity Financing | Press release | GlobeNewswire | -10.87% | -8.73% | |
| Form 6-K Adlai Nortye Ltd. For: Apr 16 | SEC filing · Form 6-K | SEC EDGAR | -10.87% | -8.73% | |
| Form 20-F Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -1.90% | -0.17% | |
| Form 6-K Adlai Nortye Ltd. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | +2.61% | +6.79% | |
| Form F-3 Adlai Nortye Ltd. | SEC filing · Form F-3 | SEC EDGAR | -1.48% | +1.48% | |
| Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations | Press release | GlobeNewswire | +2.36% | +3.54% | |
| Form 6-K Adlai Nortye Ltd. For: Feb 12 | SEC filing · Form 6-K | SEC EDGAR | +2.36% | +3.54% | |
| Adlai Nortye Announces $140.0 Million Private Placement Equity Financing | Press release | GlobeNewswire | -2.44% | -8.29% | |
| Form 6-K Adlai Nortye Ltd. For: Feb 03 | SEC filing · Form 6-K | SEC EDGAR | +0.10% | +0.80% | |
| Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China | Press release | GlobeNewswire | -21.50% | -10.00% | |
| Form 6-K Adlai Nortye Ltd. For: Dec 29 | SEC filing · Form 6-K | SEC EDGAR | -21.50% | -10.00% | |
| Morning Market Pulse: Defense-to-Data Bets, Capital Raises, and AI-Powered Platforms Shape the Open | Press release | GlobeNewswire | +0.48% | +8.96% | |
| Form 6-K Adlai Nortye Ltd. For: Dec 03 | SEC filing · Form 6-K | SEC EDGAR | -5.41% | -8.11% | |
| Adlai Nortye to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +0.75% | |
| Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | — | -0.60% | |
| Form 6-K Adlai Nortye Ltd. For: Oct 22 | SEC filing · Form 6-K | SEC EDGAR | +2.56% | +6.41% | |
| Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | -1.27% | +7.01% | |
| Form S-8 Adlai Nortye Ltd. | SEC filing · Form S-8 | SEC EDGAR | — | +0.56% | |
| Form 6-K Adlai Nortye Ltd. For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | — | -0.09% | |
| Form 6-K Adlai Nortye Ltd. For: May 30 | SEC filing · Form 6-K | SEC EDGAR | +10.11% | +2.25% | |
| Form 20-F/A Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | +2.16% | |
| Form 20-F Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | — | +6.95% | |
| Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 | Press release | GlobeNewswire | — | -3.82% | |
| Form 20-F/A Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -4.35% | |
| Form 6-K Adlai Nortye Ltd. For: Feb 14 | SEC filing · Form 6-K | SEC EDGAR | — | +3.21% | |
| Form 6-K Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -15.57% | |
| Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors | Press release | GlobeNewswire | +0.00% | +1.21% | |
| Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress | Press release | GlobeNewswire | +0.00% | +1.21% | |
| Form 6-K Adlai Nortye Ltd. For: Aug 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.21% | |
| Form 6-K Adlai Nortye Ltd. For: Jul 03 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form 6-K Adlai Nortye Ltd. For: Jun 27 | SEC filing · Form 6-K | SEC EDGAR | +9.72% | +18.90% | |
| Form 6-K Adlai Nortye Ltd. For: May 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -14.22% | |
| Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 | Press release | GlobeNewswire | +0.00% | -14.22% | |
| Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy | Press release | GlobeNewswire | — | +0.32% | |
| Form S-8 Adlai Nortye Ltd. | SEC filing · Form S-8 | SEC EDGAR | — | +3.83% | |
| Form 20-F Adlai Nortye Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | +4.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANL section they belong to.
Where else ANL is measured.
ANL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Adlai Nortye Group Ltd. - American Depositary Shares's median reaction calculated?
Every labeled ANL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 83 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ANL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.